A recent study based on Western patients has shown that Nestin is preferentially expressed in basallike breast carcinomas, predominantly expressed in triple-negative breast cancers, and suggested the use of Nestin as a marker for triple-negative breast cancer [14]. Here, NES is linked to triple-negative breast carcinoma.